Drug Watch

Topical Remetinostat Effective, Tolerable in Basal Cell Carcinoma
September 16, 2021

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.

FDA Warns About Some JAK Inhibitors
September 14, 2021

Although JAK inhibitors have shown efficacy in treating challenging conditions, federal regulators continue their safety reviews.

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays
September 02, 2021

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.